Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Palivizumab “highly cost-effective” for RSV prevention

    • 14 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Palivizumab “highly cost-effective” for RSV prevention. Pharmacoecon. Outcomes News 630, 10 (2011). https://doi.org/10.2165/00151234-201106300-00013

    Download citation

    Keywords

    • Preterm Infant
    • Respiratory Syncytial Virus
    • Respiratory Syncytial Virus Infection
    • Palivizumab
    • Monthly Dose